International Stem Cell (ISCO) Cash from Operations (2010 - 2025)
International Stem Cell (ISCO) posted quarterly Cash from Operations of 32000.0 for Q4 2025, up 143.24% year-over-year from 13155.56 in Q4 2024, and down 34.69% quarter-over-quarter from 49000.0 in Q3 2025.
International Stem Cell (ISCO) Cash from Operations (2010 - 2025) Analysis & Trends
International Stem Cell (ISCO) has reported Cash from Operations for 16 consecutive years, with 32000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Cash from Operations rose 143.24% year-over-year to 32000.0; the TTM figure through Dec 2025 stood at 8000.0 (down 38.46% YoY), while the FY2025 annual figure was 8000.0, down 38.46% from the prior year.
- Cash from Operations declined to 32000.0 in Q4 2025 per ISCO's latest filing, from 49000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 490000.0 in Q2 2023 and bottomed at 394000.0 in Q1 2021.
- Historically, Cash from Operations has averaged 750.0 across 5 years, with a median of 40500.0 in 2025.
- Annual changes were most pronounced in 2021 — Cash from Operations plunged 1916.67% — and 2023, when it jumped 1039.13%.
- International Stem Cell's Cash from Operations stood at 316000.0 in 2021, then soared by 125.0% to 79000.0 in 2022, then surged by 103.8% to 161000.0 in 2023, then sank by 145.96% to 74000.0 in 2024, then soared by 143.24% to 32000.0 in 2025.
- Business Quant data shows ISCO's Cash from Operations at 32000.0 in Q4 2025, 49000.0 in Q3 2025, and 300000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.97 Bn | 132.12 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 86.64 Bn | 78.64 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 65.55 Bn | 60.37 Bn | 1.37 Bn | - |
| 4 | Moderna | 61.26 Bn | 56.12 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 42.30 Bn | 37.20 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.66 Bn | 28.35 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.68 Bn | 10.29 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.54 Bn | 26.38 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.26 Bn | 26.42 Bn | - | 728.46 Mn |
| 10 | International Stem Cell | 3.20 Mn | 2.11 Mn | 1.46 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 32,000.00 |
| Dec 31, 2025 | 32,000.00 |
| Sep 30, 2025 | 49,000.00 |
| Sep 30, 2025 | 49,000.00 |
| Jun 30, 2025 | -300,000.00 |
| Jun 30, 2025 | -300,000.00 |
| Mar 31, 2025 | 227,000.00 |
| Mar 31, 2025 | 227,000.00 |
| Dec 31, 2024 | -74,000.00 |
| Dec 31, 2024 | -74,000.00 |
| Sep 30, 2024 | 257,000.00 |
| Sep 30, 2024 | 257,000.00 |
| Jun 30, 2024 | 23,000.00 |
| Jun 30, 2024 | 23,000.00 |
| Mar 31, 2024 | -193,000.00 |
| Mar 31, 2024 | -193,000.00 |
| Dec 31, 2023 | 161,000.00 |
| Dec 31, 2023 | 161,000.00 |
| Sep 30, 2023 | 62,000.00 |
| Sep 30, 2023 | 62,000.00 |